### Popular Weight Loss Medications and Gastrointestinal Risks A recent study has found that people taking popular weight loss medications like Ozempic, Wegovy, and Rybelsus are at a higher risk of developing serious stomach and intestinal issues compared to those taking older weight loss drugs. These medications, known as glucagon-like peptide-1 (GLP-1) receptor agonists, have been linked to a ninefold increase in the likelihood of pancreatitis, a painful inflammation of the pancreas, compared to those taking a combination of naltrexone and bupropion (brand name Contrave). The study, published in the Journal of the American Medical Association, aims to raise awareness about these potential adverse effects rather than scare people away from using these medications. The researchers emphasize that while the risk of these events is relatively low (about 1% to 2%), it is important for individuals to weigh the risks and benefits before starting these medications. For those taking GLP-1 agonists to manage diabetes, the benefits, such as lowering the risk of heart problems, might outweigh the risks. However, for otherwise healthy individuals using these drugs solely for weight loss, it is crucial to consider these potential side effects. The FDA has recently required drugmakers to include a warning about intestinal blockages on the Ozempic label. This condition, known as ileus, is another potential risk for users of these medications. Additionally, a rare side effect called gastroparesis, or stomach paralysis, has been reported. This condition occurs when the active ingredient in these medications, semaglutide, slows down digestion in the stomach. The study's findings are based on health insurance claim records for about 16 million U.S. patients. Researchers looked at individuals prescribed semaglutide or liraglutide (Saxenda) between 2006 and 2020. Although GLP-1 agonists were not approved for weight loss until 2021, the study included people with a recent history of obesity. One limitation of the study is that it could not confirm whether individuals were taking these medications solely for weight loss or also for diabetes management.